Title : Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Pub. Date : 2019 Nov 10

PMID : 31717629






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Chronic Myeloid Leukemia (CML) is a disease arising in stem cells expressing the BCR-ABL oncogenic tyrosine kinase that transforms one Hematopoietic stem/progenitor Cell into a Leukemic Stem Cell (LSC) at the origin of differentiated and proliferating leukemic cells in the bone marrow (BM). Tyrosine ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 CML-LSCs are recognized as being responsible for resistances and relapses that occur despite the advent of BCR-ABL-targeting therapies with Tyrosine Kinase Inhibitors (TKIs). Tyrosine ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens